To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

Completed · Phase 2

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.

Key facts

Study ID

NCT00141479

Run by

Solvay Pharmaceuticals

Starts

2005-05-01

Expected to finish

2006-11-01

Last updated by the study team

2015-01-16

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Schizophrenia or Schizoaffective disorder
• 18-55 years

You may not qualify if…

• Subjects who are acutely psychotic
• Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia
• Subjects at significant risk of suicide
• Subjects with a seizure disorder

Where it is running

• Site 1 — Wichita, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.